Adam C. ElNaggar

1.4k total citations
68 papers, 579 citations indexed

About

Adam C. ElNaggar is a scholar working on Reproductive Medicine, Cancer Research and Oncology. According to data from OpenAlex, Adam C. ElNaggar has authored 68 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Reproductive Medicine, 21 papers in Cancer Research and 20 papers in Oncology. Recurrent topics in Adam C. ElNaggar's work include Ovarian cancer diagnosis and treatment (24 papers), Cancer Genomics and Diagnostics (19 papers) and Endometrial and Cervical Cancer Treatments (9 papers). Adam C. ElNaggar is often cited by papers focused on Ovarian cancer diagnosis and treatment (24 papers), Cancer Genomics and Diagnostics (19 papers) and Endometrial and Cervical Cancer Treatments (9 papers). Adam C. ElNaggar collaborates with scholars based in United States, Canada and United Kingdom. Adam C. ElNaggar's co-authors include David E. Cohn, Joseph T. Santoso, Periannan Kuppusamy, John L. Hays, Todd Tillmanns, Chelsea Bolyard, K. Selvendiran, Balveen Kaur, Paul J. Goodfellow and Kristin Bixel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Adam C. ElNaggar

59 papers receiving 576 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adam C. ElNaggar United States 13 238 173 136 133 131 68 579
Laura Attademo Italy 13 225 0.9× 172 1.0× 108 0.8× 100 0.8× 103 0.8× 21 560
Domenico Sergi Italy 16 359 1.5× 178 1.0× 106 0.8× 157 1.2× 94 0.7× 54 796
Ida Paris Italy 16 370 1.6× 210 1.2× 206 1.5× 167 1.3× 241 1.8× 72 870
Miriam Rottmann Germany 11 197 0.8× 116 0.7× 113 0.8× 94 0.7× 80 0.6× 23 526
Georgia A. McCann United States 16 554 2.3× 250 1.4× 98 0.7× 135 1.0× 139 1.1× 37 897
Kiyoko Umene Japan 18 109 0.5× 397 2.3× 89 0.7× 267 2.0× 158 1.2× 32 841
Signe Frahm Bjørn Denmark 10 145 0.6× 184 1.1× 90 0.7× 239 1.8× 115 0.9× 17 669
Sophie Barrett United Kingdom 9 295 1.2× 256 1.5× 68 0.5× 161 1.2× 85 0.6× 18 660
Xi Cheng China 13 262 1.1× 251 1.5× 283 2.1× 191 1.4× 360 2.7× 30 923
Iwona Podzielinski United States 10 148 0.6× 164 0.9× 173 1.3× 165 1.2× 492 3.8× 18 768

Countries citing papers authored by Adam C. ElNaggar

Since Specialization
Citations

This map shows the geographic impact of Adam C. ElNaggar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam C. ElNaggar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam C. ElNaggar more than expected).

Fields of papers citing papers by Adam C. ElNaggar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam C. ElNaggar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam C. ElNaggar. The network helps show where Adam C. ElNaggar may publish in the future.

Co-authorship network of co-authors of Adam C. ElNaggar

This figure shows the co-authorship network connecting the top 25 collaborators of Adam C. ElNaggar. A scholar is included among the top collaborators of Adam C. ElNaggar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam C. ElNaggar. Adam C. ElNaggar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Friedman, Claire F., Anishka D'souza, Diana Bello Roufai, et al.. (2024). Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial. Gynecologic Oncology. 181. 162–169. 15 indexed citations
3.
Lee, Sarah S., Jingwen Zhang, Sara L. Bristow, et al.. (2024). A targeted panel of actionable high-risk hereditary cancer predisposition genes to identify patients with pathogenic/likely pathogenic variants (PVs) irrespective of meeting established NCCN testing criteria.. Journal of Clinical Oncology. 42(16_suppl). 10596–10596. 1 indexed citations
4.
Basu, Arnab, Meenakshi Malhotra, Adam C. ElNaggar, et al.. (2024). Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology. 8(8). e2400667–e2400667. 4 indexed citations
5.
Laliotis, George, Shivaram Cumarasamy, Samuel Rivero-Hinojosa, et al.. (2024). Performance of a tumor-informed molecular residual disease (MRD) assay in resected bladder cancer with mixed or pure variant histology: Analysis of a real-world multicenter cohort.. Journal of Clinical Oncology. 42(4_suppl). 649–649. 1 indexed citations
6.
Souter, Vivienne, et al.. (2024). Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing. SHILAP Revista de lepidopterología. 4(1). 185–185.
7.
Recio, Fernando O., Carly Bess Scalise, Melissa Lumish, et al.. (2024). Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies. Gynecologic Oncology. 182. 63–69. 11 indexed citations
8.
Lindskrog, Sia V., Karin Birkenkamp‐Demtröder, Iver Nordentoft, et al.. (2023). Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up. Clinical Cancer Research. 29(23). 4797–4807. 26 indexed citations
9.
Glaser, Gretchen, Olivia D. Lara, Bhavana Pothuri, et al.. (2022). Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study. Gynecologic Oncology. 167(2). 146–151. 4 indexed citations
10.
Xiu, Joanne, et al.. (2021). Expression of androgen receptor splice variant, AR-V7, in high-grade serous ovarian cancer. Gynecologic Oncology. 162. S157–S158. 1 indexed citations
11.
Ponnusamy, Suriyan, et al.. (2020). Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer. Journal of Personalized Medicine. 10(4). 246–246. 4 indexed citations
12.
Vanderwalde, Ari M., Axel Grothey, Daniel A. Vaena, et al.. (2020). Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting. Journal of Personalized Medicine. 10(4). 252–252. 16 indexed citations
13.
ElNaggar, Adam C., Erinn M. Hade, David M. O’Malley, et al.. (2018). Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. Gynecologic Oncology. 151(3). 501–505. 12 indexed citations
14.
ElNaggar, Adam C., et al.. (2018). Celecoxib versus ketorolac following robotic hysterectomy for the management of postoperative pain: An open-label randomized control trial. Gynecologic Oncology. 151(1). 124–128. 12 indexed citations
15.
ElNaggar, Adam C., John L. Hays, & James L. Chen. (2016). Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series. PLoS ONE. 11(6). e0156985–e0156985. 4 indexed citations
16.
ElNaggar, Adam C., John Wallbillich, Kristin Bixel, et al.. (2016). Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene. 36(2). 168–181. 96 indexed citations
17.
18.
Patil, Avinash S., Adam C. ElNaggar, Saurabh Kumar, et al.. (2014). Guided outcomes in learned efficiency model in clinical medical education: a randomized controlled trial of self-regulated learning. American Journal of Obstetrics and Gynecology. 211(5). 544.e1–544.e7. 1 indexed citations
19.
Rath, Kellie S., Shan K. Naidu, Hemant K. Bid, et al.. (2014). HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer. Cancer Research. 74(8). 2316–2327. 76 indexed citations
20.
Moore, Elizabeth S., et al.. (2011). Neonatal functional lung maturity relative to gestational age at delivery, fetal growth, and pregnancy characteristics in triplet births. The Journal of Maternal-Fetal & Neonatal Medicine. 25(1). 78–83. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Attademo Breakdown of academic impact, for papers by Domenico Sergi Breakdown of academic impact, for papers by Ida Paris Breakdown of academic impact, for papers by Miriam Rottmann Breakdown of academic impact, for papers by Georgia A. McCann Breakdown of academic impact, for papers by Kiyoko Umene Breakdown of academic impact, for papers by Signe Frahm Bjørn Breakdown of academic impact, for papers by Sophie Barrett Breakdown of academic impact, for papers by Xi Cheng Breakdown of academic impact, for papers by Iwona Podzielinski
Rankless by CCL
2026